Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1492546
This article is part of the Research Topic Research on Nanomaterials in Tumor Diagnosis and Therapy, Volume II View all articles

Nanomaterials: breaking the bottleneck of breast cancer drug resistance

Provisionally accepted
Chao Guan Chao Guan 1Yahao Han Yahao Han 2*Zhenzheng Ling Zhenzheng Ling 1*Xiang Meng Xiang Meng 3*Baolin Zhang Baolin Zhang 4*Keyan Chen Keyan Chen 2*Wanwei Dong Wanwei Dong 2*
  • 1 First Clinical Faculty, China Medical University, Shenyang, China
  • 2 Laboratory Animal Science of China Medical University, China Medical University, Shenyang, Liaoning Province, China
  • 3 China Medical University, China Medical University, Shenyang, Liaoning Province, China
  • 4 Fourth Clinical Faculty, China Medical University, Shenyang, Liaoning Province, China

The final, formatted version of the article will be published soon.

    Drug resistance poses a significant challenge in the treatment of breast cancer. In recent years, a variety of nanomaterials have been discovered and synthesized that can selectively target tumor cells and play a crucial role in the advancement of breast cancer therapies. As our understanding of tumor heterogeneity deepens, the emerging potential of nanomaterials in addressing drug resistance has garnered considerable attention. These materials not only selectively target tumor cells but also possess unique properties that make them promising options for cancer treatment, including low toxicity, excellent biocompatibility, ease of preparation, the ability to carry antitumor drugs, and customizable surface functions. In this review, we will comprehensively summarize two key developments in breast cancer treatment: the application of antitumor drugs and nanomaterials. We will explore the mechanisms by which nanomaterials improve drug resistance in breast cancer, targeted nanotherapy strategies to mitigate this resistance, and recent research advancements in anticancer nanomaterials. This overview aims to highlight the significant role of nanomaterials in breast cancer treatment and provide a theoretical framework for identifying optimal treatment strategies in the future.

    Keywords: breast cancer, nanomaterials, anticancer drugs, Drug Resistance, targeted therapy

    Received: 07 Sep 2024; Accepted: 28 Oct 2024.

    Copyright: © 2024 Guan, Han, Ling, Meng, Zhang, Chen and Dong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yahao Han, Laboratory Animal Science of China Medical University, China Medical University, Shenyang, 110122, Liaoning Province, China
    Zhenzheng Ling, First Clinical Faculty, China Medical University, Shenyang, China
    Xiang Meng, China Medical University, China Medical University, Shenyang, 110122, Liaoning Province, China
    Baolin Zhang, Fourth Clinical Faculty, China Medical University, Shenyang, 110122, Liaoning Province, China
    Keyan Chen, Laboratory Animal Science of China Medical University, China Medical University, Shenyang, 110122, Liaoning Province, China
    Wanwei Dong, Laboratory Animal Science of China Medical University, China Medical University, Shenyang, 110122, Liaoning Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.